Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

By S. Sookoian, C. Pirola. Hepatology, 2011

952 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/add93a6c0e7f0d5fe9ed660bfc1cd8a0e45c0b39

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. M. Rinella
3. K. Cusi
4. A. Sanyal
5. M. Pinzani
6. A. Baranova
7. Jan Boren
8. E. Tsochatzis

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. A. Sanyal
4. K. Cusi
5. E. Brunt
6. J. Lavine
7. A. Diehl
8. N. Chalasani

In Hepatology

1. Z. Younossi
2. M. Rinella
3. K. Cusi
4. A. Sanyal
5. E. Brunt
6. A. Diehl
7. M. Pinzani
8. J. Clark

Citations in the corpus

• The severity of NAFLD is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota (2016, background): “2-fold higher risk of developing liver fibrosis (LF).((3)) Several other factors that influence the course of the disease have been identified, such as epigenetics,((4)) hormonal status,((5)) or nutrition.”
• Non-alcoholic fatty liver disease - A global public health perspective. (2019, background): “2).17,25,27,33 As noted previously, race and ethnicity can also be considered a risk for NAFLD.5,16,20 The highest prevalence of NAFLD was observed in Hispanics, followed by non-Hispanic white individuals, and the lowest prevalence was observed in African Americans (10%).5,16,20 However, an analysis”
• The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). (2016, background): “[93] Sookoian S, Pirola CJ.”
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “Recent genome-wide association studies have associated several genetic polymorphisms, notably PNPLA-3 variants, with SH and advanced fibrosis in patients with NAFLD.((112-121)) However, testing for these genetic variants in routine clinical care is currently not advocated.”
• The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent (2016, positive): “PNPLA3 is a lipase 15-17 involved in hepatocellular lipid remodeling 17-19 and retinol metabolism 20, 21 while TM6SF2 is involved in hepatic very-low density lipoproteins (VLDL) secretion 9, 10, 22-23 .”
• Fibrosis and Adipose Tissue Dysfunction (2013, background): “GWAs approaches in other fibrotic-prone tissues, such as liver fibro-inflammation, have led to the discovery of the PLNA3 variant (Sookoian and Pirola, 2011).”
• Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults (2011, background): “In nonsteatotic subjects, the same allele also predisposes an average increase of 28% in ALT levels.(73) In addition, NASH is more frequently observed in I148M homozygotes (OR 3.”